Tegobuvir
Alternative Names: GS-333126; GS-9190Latest Information Update: 02 Oct 2021
At a glance
- Originator Gilead Sciences
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 05 Sep 2011 Gilead terminates dosing of tegobuvir in patients receiving four-drug regimens in ongoing trials
- 17 May 2011 Gilead Sciences completes enrolment in its phase II trial for Hepatitis C in Austria, Belgium, Canada, Czech Republic, England, France, Germany, Italy, Poland, Spain and USA (NCT01225380)
- 03 Apr 2011 Efficacy and adverse events data from a phase IIb trial in Hepatitis C) presented at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL-2011)